International Stem Cell Past Earnings Performance
Past criteria checks 0/6
International Stem Cell has been growing earnings at an average annual rate of 52.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 2.9% per year.
Key information
52.2%
Earnings growth rate
53.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -2.9% |
Return on equity | -240.8% |
Net Margin | -5.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How International Stem Cell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 8 | 0 | 5 | 0 |
31 Mar 24 | 8 | 0 | 5 | 0 |
31 Dec 23 | 8 | 0 | 5 | 0 |
30 Sep 23 | 8 | 0 | 5 | 0 |
30 Jun 23 | 8 | 0 | 5 | 0 |
31 Mar 23 | 8 | 0 | 5 | 0 |
31 Dec 22 | 8 | 0 | 5 | 0 |
30 Sep 22 | 8 | -1 | 5 | 0 |
30 Jun 22 | 8 | -1 | 5 | 0 |
31 Mar 22 | 8 | 0 | 6 | 0 |
31 Dec 21 | 7 | -1 | 6 | 0 |
30 Sep 21 | 7 | -1 | 6 | 0 |
30 Jun 21 | 6 | -2 | 6 | 0 |
31 Mar 21 | 6 | -3 | 6 | 0 |
31 Dec 20 | 7 | -3 | 7 | 0 |
30 Sep 20 | 8 | -5 | 8 | 0 |
30 Jun 20 | 9 | -4 | 8 | 0 |
31 Mar 20 | 10 | -4 | 9 | 0 |
31 Dec 19 | 9 | -4 | 9 | 1 |
30 Sep 19 | 9 | -3 | 9 | 1 |
30 Jun 19 | 10 | -2 | 9 | 1 |
31 Mar 19 | 11 | -2 | 8 | 2 |
31 Dec 18 | 11 | -2 | 8 | 2 |
30 Sep 18 | 11 | -2 | 7 | 2 |
30 Jun 18 | 9 | -5 | 7 | 2 |
31 Mar 18 | 8 | -4 | 7 | 2 |
31 Dec 17 | 7 | -6 | 7 | 2 |
30 Sep 17 | 7 | -3 | 7 | 2 |
30 Jun 17 | 7 | 0 | 7 | 2 |
31 Mar 17 | 8 | 10 | 7 | 3 |
31 Dec 16 | 7 | -1 | 7 | 3 |
30 Sep 16 | 7 | -5 | 7 | 2 |
30 Jun 16 | 8 | -6 | 7 | 2 |
31 Mar 16 | 8 | -16 | 7 | 2 |
31 Dec 15 | 8 | -3 | 7 | 2 |
30 Sep 15 | 7 | -6 | 7 | 4 |
30 Jun 15 | 7 | -7 | 8 | 5 |
31 Mar 15 | 7 | -12 | 8 | 6 |
31 Dec 14 | 7 | -12 | 8 | 5 |
30 Sep 14 | 7 | -11 | 9 | 4 |
30 Jun 14 | 7 | -12 | 9 | 4 |
31 Mar 14 | 7 | -10 | 9 | 3 |
31 Dec 13 | 6 | -10 | 9 | 3 |
Quality Earnings: ISCO is currently unprofitable.
Growing Profit Margin: ISCO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ISCO is unprofitable, but has reduced losses over the past 5 years at a rate of 52.2% per year.
Accelerating Growth: Unable to compare ISCO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ISCO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: ISCO has a negative Return on Equity (-240.85%), as it is currently unprofitable.